Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations
© 2024 Cadiz et al..
Aducanumab, an anti-amyloid immunotherapy for Alzheimer's disease, efficiently reduces Aβ, though its plaque clearance mechanisms, long-term effects, and effects of discontinuation are not fully understood. We assessed the effect of aducanumab treatment and withdrawal on Aβ, neuritic dystrophy, astrocytes, and microglia in the APP/PS1 amyloid mouse model. We found that reductions in amyloid and neuritic dystrophy during acute treatment were accompanied by microglial and astrocytic activation, and microglial recruitment to plaques and adoption of an aducanumab-specific pro-phagocytic and pro-degradation transcriptomic signature, indicating a role for microglia in aducanumab-mediated Aβ clearance. Reductions in Aβ and dystrophy were sustained 15 but not 30 wk after discontinuation, and reaccumulation of plaques coincided with loss of the microglial aducanumab signature and failure of microglia to reactivate. This suggests that despite the initial benefit from treatment, microglia are unable to respond later to restrain plaque reaccumulation, making further studies on the effect of amyloid-directed immunotherapy withdrawal crucial for assessing long-term safety and efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:221 |
|---|---|
| Enthalten in: |
The Journal of experimental medicine - 221(2024), 2 vom: 05. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cadiz, Mika P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
105J35OE21 |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1084/jem.20231363 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367175258 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367175258 | ||
| 003 | DE-627 | ||
| 005 | 20240210233126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1084/jem.20231363 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM367175258 | ||
| 035 | |a (NLM)38226975 | ||
| 035 | |a (PII)e20231363 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cadiz, Mika P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Cadiz et al. | ||
| 520 | |a Aducanumab, an anti-amyloid immunotherapy for Alzheimer's disease, efficiently reduces Aβ, though its plaque clearance mechanisms, long-term effects, and effects of discontinuation are not fully understood. We assessed the effect of aducanumab treatment and withdrawal on Aβ, neuritic dystrophy, astrocytes, and microglia in the APP/PS1 amyloid mouse model. We found that reductions in amyloid and neuritic dystrophy during acute treatment were accompanied by microglial and astrocytic activation, and microglial recruitment to plaques and adoption of an aducanumab-specific pro-phagocytic and pro-degradation transcriptomic signature, indicating a role for microglia in aducanumab-mediated Aβ clearance. Reductions in Aβ and dystrophy were sustained 15 but not 30 wk after discontinuation, and reaccumulation of plaques coincided with loss of the microglial aducanumab signature and failure of microglia to reactivate. This suggests that despite the initial benefit from treatment, microglia are unable to respond later to restrain plaque reaccumulation, making further studies on the effect of amyloid-directed immunotherapy withdrawal crucial for assessing long-term safety and efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a aducanumab |2 NLM | |
| 650 | 7 | |a 105J35OE21 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Gibson, Katelin A |e verfasserin |4 aut | |
| 700 | 1 | |a Todd, Kennedi T |e verfasserin |4 aut | |
| 700 | 1 | |a Nascari, David G |e verfasserin |4 aut | |
| 700 | 1 | |a Massa, Nashali |e verfasserin |4 aut | |
| 700 | 1 | |a Lilley, Meredith T |e verfasserin |4 aut | |
| 700 | 1 | |a Olney, Kimberly C |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Amin, Md Mamun |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Holtzman, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Fryer, John D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of experimental medicine |d 1896 |g 221(2024), 2 vom: 05. Feb. |w (DE-627)NLM000005967 |x 1540-9538 |7 nnns |
| 773 | 1 | 8 | |g volume:221 |g year:2024 |g number:2 |g day:05 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1084/jem.20231363 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 221 |j 2024 |e 2 |b 05 |c 02 | ||